

## CCR Translations

- Barriers to Integrating Gene Profiling for Stage II Colon Cancer.** Scott Kopetz and James L. Abbruzzese.....7451  
  *Commentary on Jorissen et al., p. 7642*

- Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/ $\beta$ -catenin Crosstalk Leads to Tumor Cell Death.** Benjamin D. Zeitlin, Lee M. Ellis, and Jacques E. Nör .....7453  
  *Commentary on Naik et al., p. 7529*

## CCR Drug Update

- Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.** Varsha Gandhi and Jan A. Burger .....7456

## Molecular Pathways

- Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.** Bryan P. Toole.....7462

## CCR Special Focus

- From the Editor.** Susan E. Bates .....7469

- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.** Lee M. Ellis and Daniel J. Hicklin .....7471

- Resistance to Trastuzumab in Breast Cancer.** Paula R. Pohlmann, Ingrid A. Mayer, and Ray Mernaugh.....7479

- Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.** Michaela S. Banck and Axel Grothey .....7492

- Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.** Peter S. Hammerman, Pasi A. Jänne, and Bruce E. Johnson.....7502

- Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.** Ann W. Gramza, Christopher L. Corless, and Michael C. Heinrich.....7510

- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.** Dragana Milojkovic and Jane Apperley .....7519



## Human Cancer Biology

- Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant  $\beta$ -Catenin Activation in Colon Cancer.** Snehal Naik, Robin S. Dothager, Jayne Marasa, Cory L. Lewis, and David Piwnica-Worms .....7529

- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.** Michael A. Davies, Katherine Stemke-Hale, E. Lin, Carmen Tellez, Wanleng Deng, Yennu N. Gopal, Scott E. Woodman, Tiffany C. Calderone, Zhenlin Ju, Alexander J. Lazar, Victor G. Prieto, Kenneth Aldape, Gordon B. Mills, and Jeffrey E. Gershenwald .....7538

- Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.** Valentina Monica, Giorgio V. Scagliotti, Paolo Ceppi, Luisella Righi, Alberto Cambieri, Marco Lo Iacono, Silvia Saviozzi, Marco Volante, Silvia Novello, and Mauro Papotti .....7547

- Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma.** Marvaretta Stevenson, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, Sascha A. Tuchman, Jeffrey Crawford, Gordana Vlahovic, Neal Ready, Mark Onaitis, and Anil Potti .....7553
- Smoking-Related Gene Expression in Laser Capture–Microdissected Human Lung.** Xiang-Lin Tan, Tao Wang, Shengli Xiong, Shalini V. Kumar, Weiguo Han, and Simon D. Spivack.....7562
- 14-3-3 $\eta$  Amplifies Androgen Receptor Actions in Prostate Cancer.** Mark A. Titus, Jiann-an Tan, Christopher W. Gregory, O. Harris Ford, Romesh R. Subramanian, Haian Fu, Elizabeth M. Wilson, James L. Mohler, and Frank S. French.....7571
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.** Alison C. Young, Rachel A. Craven, Dena Cohen, Claire Taylor, Christopher Booth, Patricia Harnden, David A. Cairns, Dewi Astuti, Walter Gregory, Eamonn R. Maher, Margaret A. Knowles, Adrian Joyce, Peter J. Selby, and Rosamonde E. Banks .....7582
- Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides.** Mark G. Slomiany, Lu Dai, Lauren B. Tolliver, G. Daniel Grass, Yiping Zeng, and Bryan P. Toole .....7593

## Cancer Therapy: Preclinical

- Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.** Wanqing Liu, Lijun He, Jacqueline Ramírez, and Mark J. Ratain.....7602
- Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity.** Teresa Puig, Carlos Turrado, Bellinda Benhamú, Helena Aguilar, Joana Relat, Silvia Ortega-Gutiérrez, Gemma Casals, Pedro F. Marrero, Ander Urruticoechea, Diego Haro, María Luz López-Rodríguez, and Ramon Colomer.....7608
- ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity.** Robert A.B. van Waterschoot, Rhandy M. Eman, Els Wagenaar, Cornelia M.M. van der Kruijssen, Hilde Rosing, Jos H. Beijnen, and Alfred H. Schinkel.....7616
- Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.** Jennifer A. Westwood, Nicole M. Haynes, Janelle Sharkey, Nicole McLaughlin, Hollie J. Pegram, Reto A. Schwendener, Mark J. Smyth, Phillip K. Darcy, and Michael H. Kershaw .....7624
- Transforming Growth Factor- $\beta$ -Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.** Cynthia C.T. Sprenger, Kathleen Haugk, Shihua Sun, Ilsa Coleman, Peter S. Nelson, Robert L. Vessella, Dale L. Ludwig, Jennifer D. Wu, and Stephen R. Plymate.....7634

## Imaging, Diagnosis, Prognosis

- Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.** Robert N. Jorissen, Peter Gibbs, Michael Christie, Saurabh Prakash, Lara Lipton, Jayesh Desai, David Kerr, Lauri A. Aaltonen, Diego Arango, Mogens Kruhøffer, Torben F. Ørntoft, Claus Lindbjerg Andersen, Mike Gruidl, Vidya P. Kamath, Steven Eschrich, Timothy J. Yeatman, and Oliver M. Sieber .....7642
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.** Angelica Calleri, Anna Bono, Vincenzo Bagnardi, Jessica Quarna, Patrizia Mancuso, Cristina Rabascio, Silvia Dellapasqua, Elisabetta Campagnoli, Yuval Shaked, Aron Goldhirsch, Marco Colleoni, and Francesco Bertolini.....7652

**The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins.** M. Luana Poeta, Judith Manola, David Goldenberg, Arlene Forastiere, Joseph A. Califano, John A. Ridge, Jarrard Goodwin, Daniel Kenady, John Saunders, William Westra, David Sidransky, and Wayne M. Koch .....7658

**Differential Proteomics Identifies Protein Biomarkers That Predict Local Relapse of Head and Neck Squamous Cell Carcinomas.** Tienek B.M. Schaaij-Visser, A. Peggy Graveland, Sharon Gauci, Boudewijn J.M. Braakhuis, Marijke Buijze, Albert J.R. Heck, Dirk J. Kuik, Elisabeth Bloemena, C. René Leemans, Monique Slijper, and Ruud H. Brakenhoff .....7666

**Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine.** Brian D. Snyder, Marsha A. Cordio, Ara Nazarian, S. Daniel Kwak, David J. Chang, Vahid Entezari, David Zurakowski, and Leroy M. Parker .....7676

**miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer.** Patsy Siok Hwa Soon, Lyndal J. Tacon, Anthony J. Gill, Christopher P. Bambach, Mark S. Sywak, Peter R. Campbell, Michael W. Yeh, Steven G. Wong, Roderick J. Clifton-Bligh, Bruce G. Robinson, and Stan B. Sidhu .....7684

**Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.** Joseph A. Sparano, Lori J. Goldstein, Barrett H. Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L. Baehner, Roberto Bugarini, Steve Rowley, Edith Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Jr., and Robert Gray .....7693



## Cancer Therapy: Clinical

**A Phase I Clinical Trial of CHT-25 a <sup>131</sup>I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.** Gairin Dancey, John Violet, Alessandra Malaroda, Alan J. Green, Surinder K. Sharma, Roslyn Francis, Shokri Othman, Sweta Parker, John Buscombe, Natalie Griffin, Pei-San Chan, Anmol Malhotra, Nicholas Woodward, Alan Ramsay, Philip Ross, T. Andrew Lister, Peter Amlot, Richard Begent, and Christopher McNamara .....7701

**Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.** Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott, Amy Kramer, Lydia Giles, Kristi Gramlich, Mary Carberry, Andrea B. Troxel, Richard Letrero, Katherine L. Nathanson, Michael B. Atkins, Peter J. O'Dwyer, and Keith T. Flaherty .....7711

**Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck.** John Nemunaitis, Gary Clayman, Sanjiv S. Agarwala, William Hrushesky, James R. Wells, Charles Moore, John Hamm, George Yoo, Jose Baselga, Barbara A. Murphy, Kerstin A. Menander, Laura L. Licato, Sunil Chada, Robert D. Gibbons, Magali Olivier, Pierre Hainaut, Jack A. Roth, Robert E. Sobol, and W. Jarrard Goodwin .....7719

**Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.** Han Chong Toh, Who-Whong Wang, Whay Kuang Chia, Pia Kvistborg, Li Sun, Kelly Teo, Yee Peng Phoon, Yatanar Soe, Sze Huey Tan, Siew Wan Hee, Kian Fong Foo, Simon Ong, Wen Hsin Koo, Mai-Britt Zocca, and Mogens H. Claesson .....7726

## Susceptibility and Prevention

**Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients.** Chanjuan Shi, Alison P. Klein, Michael Goggins, Anirban Maitra, Marcia Canto, Syed Ali, Richard Schulick, Emily Palmisano, and Ralph H. Hruban .....7737

**High Innate Production Capacity of Proinflammatory Cytokines Increases Risk for Death from Cancer: Results of the PROSPER Study.** Stella Trompet, Anton J.M. de Craen, Simon Mooijaart, David J. Stott, Ian Ford, Naveed Sattar, Wouter Jukema, and Rudi G.J. Westendorp .....7744

---

## Letters to the Editor

- Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.** Keith T. Flaherty and Marcia S. Brose .....7749
- Reply to the Letter to the Editor.** Nilofer S. Azad, Jeanny B. Aragon-Ching, and Heidi H. Kong .....7749

## Corrections

- Correction: A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors**.....7751
- Correction: A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients** .....7751

## Acknowledgment to Reviewers

- Acknowledgment to Reviewers** .....7752

---

## About the Cover

In a targeted RNA interference screen of the human kinome, VEGFR1/Flt1 was identified as a positive regulator of Wnt/ $\beta$ -catenin signaling and found to be synthetic lethal in the context of aberrant Wnt activation, such as that found in colon cancer. Even in the presence of siRNA targeting VEGFR1, immunofluorescence analysis showed nuclear translocation of  $\beta$ -catenin upon stimulation with Wnt. Thus, VEGFR1 likely regulates Wnt signaling at the level of posttranslational modification of  $\beta$ -catenin and represents a potential therapeutic target for treatment of Wnt/ $\beta$ -catenin—addicted cancers. For further details, please see Naik and colleagues on page 7529 in this issue.

